{"id":988350,"date":"2026-08-03T09:04:07","date_gmt":"2026-08-03T13:04:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/"},"modified":"2026-08-03T09:04:07","modified_gmt":"2026-08-03T13:04:07","slug":"medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/","title":{"rendered":"Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom"},"content":{"rendered":"

\nDr. Mehmud\u2019s appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev
\n<\/h2>\n
\n

PHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (\u201cMedicus\u201d or the \u201cCompany\u201d), a biotech\/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced the appointment of Faisal Mehmud, MD, MRCP<\/strong>, as\u00a0Chief Executive Officer of Antev Limited, United Kingdom (\u201cAntev\u201d)<\/strong>, the Company\u2019s United Kingdom subsidiary, effective August 30, 2026<\/strong>.<\/p>\n

Dr. Mehmud will continue to serve as\u00a0Chief Medical Officer of Medicus<\/strong>\u00a0and\u00a0Co-Chairman of Antev <\/strong>providing unified scientific, clinical, regulatory and operational leadership as the Company advances the global development of\u00a0Teverelix\u00ae<\/strong> across multiple indications, including advanced prostate cancer, acute urinary retention and women\u2019s health.<\/p>\n

The appointment further strengthens Medicus\u2019 integrated leadership structure by aligning the scientific, clinical and regulatory leadership of Antev under an experienced global pharmaceutical executive as the Company advances Teverelix\u00ae through key regulatory interactions, late-stage clinical development and strategic partnering activities.<\/p>\n

\n \u201cWe are delighted to appoint Faisal as Chief Executive Officer of Antev in addition to his role as Co-Chairman of Antev\u2019s Board of Directors,\u201d stated\u00a0<\/em>
\n
\n Dr. Raza Bokhari, Medicus Executive Chairman and CEO<\/em>
\n <\/strong>
\n . \u201cSince joining Medicus as Chief Medical Officer, Faisal has become an integral member of our executive leadership team. His more than 20 years of global pharmaceutical leadership experience, deep understanding of Teverelix\u00ae and experience leading global clinical development, regulatory and medical organizations position him well to lead Antev through its next phase of clinical development and execution of corporate mandates.\u201d<\/em>\n <\/p>\n

Dr. Mehmud succeeds\u00a0Amit Kohli, who has served as interim Chief Executive Officer of Antev since its acquisition by Medicus which was completed on August 29, 2025. As contemplated at the time of the acquisition, Mr. Kohli agreed to remain with the Company for one year to ensure a successful transition of the business, its operations, development programs and key stakeholder relationships.<\/p>\n

Dr. Mehmud brings more than 20 years of global biopharmaceutical leadership experience spanning clinical development, medical affairs, regulatory strategy, pharmacovigilance and scientific communications across oncology, hematology, rare diseases and primary care. Throughout his career, he has held senior leadership roles supporting the clinical development, regulatory approval, lifecycle management and commercialization of innovative medicines, including small molecules, biologics, monoclonal antibodies, cell therapies and cytotoxic chemotherapies. He has led multidisciplinary global organizations responsible for designing and executing late-stage clinical development programs, generating real-world evidence, supporting regulatory interactions, and developing medical strategies that have advanced therapies from early clinical development through global commercialization.<\/p>\n

Prior to joining Medicus, Dr. Mehmud held senior global leadership positions at Pfizer, GSK, Bristol Myers Squibb, Novartis and Sanofi<\/strong>. His responsibilities included global clinical development, precision medicine, medical affairs, regulatory strategy, real-world evidence generation and scientific communications supporting innovative medicines across multiple therapeutic areas. Throughout his career, Dr. Mehmud has led multidisciplinary international teams supporting global regulatory interactions, clinical development and evidence generation for innovative medicines.<\/p>\n

Dr. Mehmud earned his medical degree from the\u00a0University of Cambridge<\/strong>\u00a0and completed postgraduate training in Internal Medicine in the United Kingdom. He holds postgraduate qualifications in Internal Medicine<\/strong> and Pharmaceutical Medicine<\/strong>\u00a0from the\u00a0Royal College of Physicians (UK)<\/strong>. Dr. Mehmud is a\u00a0Member of the Royal College of Physicians (MRCP)<\/strong> and is licensed by the\u00a0UK General Medical Council<\/strong>.<\/p>\n

\n About Antev Limited:<\/strong>
\n \n <\/p>\n

Antev Limited is a UK based subsidiary of Medicus Pharma Ltd., is a clinical biotechnology company developing Teverelix\u00ae<\/strong>, a next-generation GnRH antagonist for multiple urologic and women\u2019s health indications, including advanced prostate cancer, acute urinary retention associated with benign prostatic hyperplasia and endometriosis.<\/p>\n

\n For further information contact:<\/strong>\n <\/p>\n

Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com<\/u><\/a><\/p>\n

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicuspharma.com<\/u><\/a><\/p>\n

\n
\n About Medicus Pharma Ltd.<\/em>
\n <\/strong>\n <\/p>\n

\n Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech\/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is actively engaged in multiple countries across three continents.<\/em>\n <\/p>\n

\n The Company\u2019s current key therapeutic assets are:<\/em>\n <\/p>\n

\n
\n SkinJect\u00ae<\/em>
\n <\/strong>
\n
\n , a novel localized immuno-oncology precision product<\/em>
\n <\/strong>
\n focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) and <\/em>
\n
\n Gorlin Syndrome<\/em>
\n <\/strong>
\n , a rare autosomal dominant disease also called nevoid BCC syndrome.<\/em>\n <\/p>\n

\n
\n Teverelix\u00ae, a next-generation GnRH antagonist,<\/em>
\n <\/strong>
\n is a product under clinical development for cardiovascular high-risk advanced prostate cancer patients and patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate, and endometriosis.<\/em>\n <\/p>\n

\n Medicus\u2019 strategy is to advance select programs through Phase 2 proof-of-concept, key clinical and regulatory inflection points that substantially <\/em>
\n reduce development risk and increase attractiveness to potential pharmaceutical partners. By generating decision-grade clinical, regulatory and operational datasets, the Company seeks to create opportunities for strategic collaborations, regional licensing transactions and broader commercialization partnerships with established pharmaceutical companies. As data matures across its programs, Medicus intends to continue building differentiated development packages designed to maximize asset value while maintaining capital efficiency and development focus.<\/em>\n <\/p>\n

\n
\n Cautionary Notice on Forward-Looking Statements<\/em>
\n <\/strong>\n <\/p>\n

\n Certain information in this news release constitutes \u201cforward-looking information\u201d under applicable securities laws. \u201cForward-looking information\u201d is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the development of SkinJect\u00ae and the potential benefits thereof for those suffering with Gorlin Syndrome, Antev\u2019s future, the development of Teverelix\u00ae and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix\u00ae for AURr, <\/em>
\n cardiovascular high-risk advanced <\/em>
\n prostate cancer, women\u2019s health indications like endometriosis, and the potential market opportunities related thereto. Forward-looking statements are often but not always, identified by the use of such terms as \u201cmay\u201d, \u201con track\u201d, \u201caim\u201d, \u201cmight\u201d, \u201cwill”, \u201cwill likely result\u201d, \u201ccould,\u201d \u201cdesigned,\u201d \u201cwould\u201d, \u201cshould\u201d, \u201cestimate\u201d, \u201cplan\u201d, \u201cproject\u201d, \u201cforecast\u201d, \u201cintend\u201d, \u201cexpect\u201d \u201canticipate\u201d, \u201cbelieve\u201d, \u201cseek\u201d, \u201ccontinue\u201d, \u201ctarget\u201d, \u201cpotential\u201d or the negative and\/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company\u2019s annual report on form 10-K for the year ended December 31, 2025, and in the Company\u2019s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company\u2019s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.<\/em>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Dr. Mehmud\u2019s appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev PHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (\u201cMedicus\u201d or the \u201cCompany\u201d), a biotech\/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced the appointment of Faisal Mehmud, MD, MRCP, as\u00a0Chief Executive Officer of Antev Limited, United Kingdom (\u201cAntev\u201d), the Company\u2019s United Kingdom subsidiary, effective August 30, 2026. Dr. Mehmud will continue to serve as\u00a0Chief Medical Officer of Medicus\u00a0and\u00a0Co-Chairman of Antev providing unified scientific, clinical, regulatory and operational leadership as the Company advances the global development of\u00a0Teverelix\u00ae across multiple indications, including advanced prostate cancer, acute urinary retention and women\u2019s health. The appointment further … <\/p>\n

Continue reading “Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-988350","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMedicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dr. Mehmud\u2019s appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev PHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (\u201cMedicus\u201d or the \u201cCompany\u201d), a biotech\/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced the appointment of Faisal Mehmud, MD, MRCP, as\u00a0Chief Executive Officer of Antev Limited, United Kingdom (\u201cAntev\u201d), the Company\u2019s United Kingdom subsidiary, effective August 30, 2026. Dr. Mehmud will continue to serve as\u00a0Chief Medical Officer of Medicus\u00a0and\u00a0Co-Chairman of Antev providing unified scientific, clinical, regulatory and operational leadership as the Company advances the global development of\u00a0Teverelix\u00ae across multiple indications, including advanced prostate cancer, acute urinary retention and women\u2019s health. The appointment further … Continue reading "Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-03T13:04:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjE3OSM3NzU0NjkyIzIzMDUxNzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom\",\"datePublished\":\"2026-08-03T13:04:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\\\/\"},\"wordCount\":1176,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMjE3OSM3NzU0NjkyIzIzMDUxNzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\\\/\",\"name\":\"Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMjE3OSM3NzU0NjkyIzIzMDUxNzk=\",\"datePublished\":\"2026-08-03T13:04:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMjE3OSM3NzU0NjkyIzIzMDUxNzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMjE3OSM3NzU0NjkyIzIzMDUxNzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/","og_locale":"en_US","og_type":"article","og_title":"Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom - Market Newsdesk","og_description":"Dr. Mehmud\u2019s appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev PHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (\u201cMedicus\u201d or the \u201cCompany\u201d), a biotech\/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced the appointment of Faisal Mehmud, MD, MRCP, as\u00a0Chief Executive Officer of Antev Limited, United Kingdom (\u201cAntev\u201d), the Company\u2019s United Kingdom subsidiary, effective August 30, 2026. Dr. Mehmud will continue to serve as\u00a0Chief Medical Officer of Medicus\u00a0and\u00a0Co-Chairman of Antev providing unified scientific, clinical, regulatory and operational leadership as the Company advances the global development of\u00a0Teverelix\u00ae across multiple indications, including advanced prostate cancer, acute urinary retention and women\u2019s health. The appointment further … Continue reading \"Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-03T13:04:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjE3OSM3NzU0NjkyIzIzMDUxNzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom","datePublished":"2026-08-03T13:04:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/"},"wordCount":1176,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjE3OSM3NzU0NjkyIzIzMDUxNzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/","name":"Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjE3OSM3NzU0NjkyIzIzMDUxNzk=","datePublished":"2026-08-03T13:04:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjE3OSM3NzU0NjkyIzIzMDUxNzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjE3OSM3NzU0NjkyIzIzMDUxNzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-appoints-dr-faisal-mehmud-as-chief-executive-officer-of-antev-limited-united-kingdom\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/988350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=988350"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/988350\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=988350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=988350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=988350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}